These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 28768162)

  • 1. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
    Lee HT; Lee SH; Heo YS
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing protein flexibility reveals a mechanism for selective promiscuity.
    Pabon NA; Camacho CJ
    Elife; 2017 Apr; 6():. PubMed ID: 28432789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
    Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
    Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
    Tang S; Kim PS
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
    Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
    Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
    Roither B; Oostenbrink C; Schreiner W
    BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.
    Philips EA; Garcia-España A; Tocheva AS; Ahearn IM; Adam KR; Pan R; Mor A; Kong XP
    J Biol Chem; 2020 Apr; 295(14):4372-4380. PubMed ID: 31882544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
    Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
    J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and interactions of the human programmed cell death 1 receptor.
    Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ
    J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
    Almahmoud S; Zhong HA
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
    Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
    Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
    Commun Biol; 2019; 2():392. PubMed ID: 31667366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
    Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
    J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
    Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
    Molecules; 2019 May; 24(11):. PubMed ID: 31151293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.